MGI Pharma
Executive Summary
Company "to terminate all development efforts for MGI 136"; the compound (diethyldithiocarbamate) was in Phase III trials as a chemoprotective agent. Minneapolis-based MGI Pharma suspended the trials in February when an interim analysis of the data showed that patients on MGI-136 appeared to have a decreased tolerance for chemotherapy ("The Pink Sheet" Feb. 17, T&G-11)....